 SAN DIEGO--BUSINESS WIRE--- GOSS--Gossamer Bio, Inc. Nasdaq: GOSS, a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will present data relevant to GB1275 at the 35th Annual Meeting of the Society for Immunotherapy of Cancer SITC, to be held virtually from November 9-14, 2020. This includes clinical and biomarker data from the ongoing GB1275 